← All trials
NCT02861950
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2017
- Primary completion
- Jul 1, 2018
- Completion date
- Jul 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 490
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Colorado, DenverLead sponsor
- University of Colorado, DenverOverall official - principal investigator
- Stanford UniversityCollaborator
- Northwestern UniversityCollaborator
- Children's Medical Center DallasCollaborator
- University of New MexicoCollaborator
- Oregon Health and Science UniversityCollaborator
- University of WashingtonCollaborator
- Baylor UniversityCollaborator
- University of Texas at HoustonCollaborator
- University of WisconsinCollaborator
- Emory UniversityCollaborator
- Joe DiMaggio Children's HospitalCollaborator
- Dartmouth UniversityCollaborator
- Indiana UniversityCollaborator
- Harvard UniversityCollaborator
- University of MississippiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.